Introduction: Nicorandil is a popular
INTRODUCTION
Nicorandil was first used in 1984 in Japan for the management of angina and has been available in the UK since 1994. Despite not being Food and Drug Administration approved, it is considered a safe and tolerable drug following observations from trials, everyday practice and prescription event monitoring studies. In one of the largest trials ever conducted, the IONA [1, 2] , withdrawals from study medication occurred in 39.1% of participants (31.6% in the placebo group). It is also quite a popular choice.
Prescription cost analysis data, containing information on the number of items and the net ingredient cost of all community prescriptions dispensed in England, shows average monthly expenses reaching 833,184 GBP between August 2013 and January 2014 [3] . Health Boards in Scotland have spent 2,863,347 GBP on nicorandil preparations in 2013 [4] . Nicorandil is recommended as third-line medication for people on beta-blocker or calcium channel-blocker monotherapy whose symptoms are not controlled and any alternative treatment option (calcium channel blocker or beta-blocker) is contraindicated or not tolerated [5] . In 1997, the drug was called in question as a cause of severe oral ulcers [6] : successively, an association between nicorandil and various lesions of the gastrointestinal (GI) tract was endorsed.
PHARMACODYNAMICS
The use of nicorandil results in arterial and venous dilation due to a dual mechanism of action. It features a nicotinamide moiety, responsible for the effect on K ? adenosine triphosphate (ATP) channels, coupled to nitric oxide (NO) [7] [8] [9] [10] .
Reduced sensitivity of the ATP-dependent potassium channel to ATP augments the flow of K ? through the sarcolemmal potassium channel. This is followed by a hyperpolarization that closes
voltage-dependent calcium channels in the cell membrane and increases calcium efflux through the sodium channel exchanger.
Additionally, NO stimulates the enzyme guanylate cyclase which increases cyclic guanosine monophosphate production and consequently decreases cytosolic-free calcium in vascular smooth muscle [11, 12] .
Pharmacokinetics
The recommended dose of nicorandil ranges from 10 to 20 mg twice daily up to 30 mg twice daily [13, 14] . The drug is absorbed 30-45 min after ingestion with minimal first-pass metabolism in the liver and thus features high bioavailability [15] . The bond to albumin and plasma protein is weak and most of the drug circulates unbound [15] . A steady state is achieved on the fourth day and repeated administrations cause accumulation of nicorandil and its metabolites (with little effect on the cardiovascular system) [16] . Following hepatic metabolism, the metabolites are mostly eliminated in the urine. The initial renal clearance has been estimated as 10 mL/min, although there appears to be a second distribution phase, with low plasma levels after 8 h, possibly caused by a slow release from the vascular tissues [16] . About 1% of the dose is excreted unchanged in urine and fecal excretion of the drug accounts for \2%. 
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
171 sources were included in the review and 92 used for the quantitative synthesis from an initial 2241 search results. 71 articles were included from other sources, such as the WHO-ADR, MHRA databases, the unpublished database of GI ADR observed during the IONA trial and bibliographies of screened articles (Fig. 2) . between nicorandil and ulceration was not considered due to a lack of a dose-response effect [51] . Therefore, the hypothesis endorsing a link between the drug and the oral ulcers was rejected. Successive reviews did not emphasize an ulcerative tendency of nicorandil [52] [53] [54] .
General GI Side Effects
It is now evident that the onset of ulceration involving the skin, mucosa or other tissues typically occurs following a period ranging from a few weeks to years. 
Anatomical Division

Oral Cavity
Oral ulceration is the most commonly reported GI side effect of nicorandil. With 5 participants over 2565 in the experimental group, the overall incidence of oral ulcers is estimated as 0.2%, using data from the IONA trial, which featured a mean follow-up of 1.6 years. In another observational study, a much higher proportion of oral ulcerations was seen (in 5 patients out of 100): in three cases, examination showed a pattern of chronic oral ulceration; in the other two cases there was a positive history for buccal ulcerations [19] .
According to Cribier et al. [58] , three out their seven patients with oral ulcers already had a history of chronic aphthous ulcers: nonetheless, the ulcers that occurred while on nicorandil were unusually large and painful and did not show resolution after 3-4 days. A history of aphthous stomatitis could be a ''cofactor'' [19, 59] , as it was present in 23% of cases in one review of nicorandil-induced oral ulcerations [60] . Reichert et al. [6] was the first to describe mouth ulcers in two patients, mimicking a pattern of major recurrent aphthous stomatitis (MaRAS) [61] . Ulcers in Deep, punched out appearances have been described [55] in addition to those of superficial extent only [62] . Irregular, linear, oval or round borders have been reported [55, 58, 63] . The base of the lesions is often described as yellow [63] or with a gray pseudomembrane [64] . Table 2 ).
Aphthous stomatitis, oral and gingival ulcerations and erosions are commonly reported events in the MHRA, constituting roughly 28% of the GI ADRs; the proportion is over 29% in the WHO database, excluding potentially significant events such as ''glossitis'' or ''dysphagia''.
Salivary Glands
Very rare reports of ''dry mouth'' have been made following exposure to nicorandil; neither the MHRA nor the WHO databases contain consistent data associating it with salivary gland pathology.
Pharynx
Isolated involvement of the pharynx appears uncommon. It is highlighted three times in the WHO list in the context of a total of 914 GI ADR (thus, featuring a relative frequency of 0.33%), with all reports originating from the UK.
Cupples et al. [75] [95, 96] .
Pancreas
Only one episode of pancreatitis has been described in the UK and appears on the MHRA and WHO reports. Overall, involvement of the pancreas does not appear to be a concern.
Liver and Biliary System
Excepting deranged liver function and jaundice in the pharmacovigilance databases, there is lack of information to sustain a relevant involvement of the hepatobiliary system following exposure to nicorandil. Isolated events of hepatic failure, hyperbilirubinemia, jaundice and abnormal liver tests were noted and followed up in the PEM study, but no further information about causality assessment was provided [50] . Griffiths [97] replied to the article citing his experience with a 74-year-old woman, found to have isolated ulcers at the hepatic flexure and the distal small bowel. Swinscoe et al. [104] presented a case of ileal involvement, resulting in rectal bleeding. Remission was not obtained after withdrawal of aspirin and non-steroidal anti-inflammatory drugs, but was finally achieved when nicorandil was suspended. The histological features were consistent with ischemia rather than inflammation.
The literature reports the involvement of the ileum in the context of surgical stomata as well 
Cecum and Ascending Colon
Isolated involvement of the cecum by ulceration is recognized. Lee et al. [108] reported two individuals with cecal ulcerations in their series of eight patients. The histology featured only inflammatory changes, without ischemic features. A previous report [109] described similar lesions in the transverse and right colon of a 76-year-old lady. Histology was not suggestive of inflammatory bowel disease or mesenteric ischemia. Ramos et al. [110] gave notice of a sigmoid-cecal fistula in a 76-year-old man on nicorandil, who suffered from a 6-month history of diarrhea; again, no element was found to suggest a neoplastic or inflammatory origin. The WHO list features one case of cecum perforation (0.1%), flagged in the UK and resulting in a life-threatening but not fatal event. [157] argued that nicorandil, in a dose-dependent manner, dephosphorylates myosin and so hinders the actin filament contraction that is necessary for cell migration, as would be required to repair mucosal microtrauma and surgical wounds. Nicorandil has been shown to inhibit endothelial cell mitogenesis and proliferation in experimental settings [158, 159] . In animal studies it has shown to hamper the inflammatory pathway, decreasing the production and release of tumor necrosis factor-alpha (TNF-a) and other mediators that pave the way for the healing process [160, 161] . Trechot et al. [162] [163] [164] [165] Nicotinic acid, or niacin, is a water-soluble B-complex vitamin that has been used to treat dyslipidemia, as it is able to affect all lipid parameters [166] . In adipose tissue, niacin inhibits the lipolysis of triglycerides by hormone-sensitive lipase. In previous systematic reviews, it has been associated with increased serum high-density lipoprotein cholesterol [167] and reduction of cardiovascular events and stroke [168] , but its routine use in prevention is controversial [169] . Its deficiency causes pellagra and its side effects are mainly represented by cutaneous flushing, Nicorandil's activity on ATP-sensitive potassium channels would determine a local toxic action with electrolyte disturbance
Rest of Colon and Rectum
The activity on ATP-sensitive potassium channels commences shortly after the drug absorption: differences in dosage and time of the onset of ulcerations are then difficult to explain Hypersensitivity hypothesis [20] Hypersensitivity towards the drug would manifest in non-keratinizing squamous epithelium lining areas of the oral cavity and lower anal canal
The ulcerative tendency of nicorandil goes well beyond squamous epithelia of the oral cavity and anal canal; the lesions are frequently limited to a single well-defined area(s), despite a systemic exposure to the medication Myosin dephosphorilation [157] Nicorandil would dephosphorilate myosin filaments, thus hindering fibroblast's contractile capacity, thus wound healing
Nicorandil would then have a limited role in the lesion aetiology and would only delay or hinder the healing process. In many cases, there is no clear history of triggering or promoting factor apart from nicorandil exposure Toxic metabolites [23, [162] [163] [164] There would be a gradual accumulation of metabolites, i.e. nicotinamide and nicotinic acid, after saturation of the NAD/NADP pool. While the drug and some metabolites would still induce vasodilation, other derived molecules would have an ulcerogenic effect (i.e. nicotinic acid)
The enzymatic pathway involved in nicorandil metabolism has not been fully characterised and there is lack of data with regards to pharmacokinetic activity in hepatic impairment. Its allegedly ulcerogenic metabolite, nicotinic acid or niacin, does cause flushing and pruritus. Nevertheless, it is also associated with hepatotoxicity and this does not appear to be an accordingly frequent ADR dry skin, pruritus, skin rashes and acanthosis nigricans, as well as gout exacerbation and serious hepatotoxicity (high serum transaminases and hyperglycemia [166] ). The hepatobiliary system does not appear to be commonly and significantly affected by nicorandil exposure. Although this is not in keeping with the hypothesis above [162] [163] [164] [165] , the accumulation of the allegedly ulcerogenic molecule would take place at the tissue level, likely without high serum concentrations observed in patients under niacin therapy. There is a tendency to develop mucosal ulcerations over weeks with high dosages of nicorandil; nonetheless, oral ulcerations have been reported with small doses and a concomitantly increased period of time for the onset. It also appears that the involvement of the colon and rectum takes place in older and possibly more frail patients (Table 3) . Topical and systemic steroids have been widely used to relieve symptoms from oral ulcers with little or no effect, as well as colchicine, antifungals, aciclovir or various antibiotics [6, 12, 55, 58, 62-65, 67, 71, 72, 83, 91] ; no healing has ever been observed, without a simultaneously enforced withdrawal or dose reduction of nicorandil. In anal ulcers, conservative measures (e.g., dressings, glyceryl trinitrate ointment or botulinum injection) without suspension of nicorandil are described to be ineffective [117, 134, 149] , as is surgical intervention [123, 130, 134, 137, 151] . It is probable that pharmacogenetics are involved and some individuals preferentially metabolize the drug into more ulcerogenic daughter molecules.
While the most common sites for GI ADR are the oral cavity and distal tract (28-29 % and 27-31 % of all GI ADR, respectively, according to WHO and MHRA), various reports have emphasized how the drug can cause lesions elsewhere: non-GI ulcerations occur in compromised, vulnerable regions, e.g., in the context of a large inguino-scrotal hernia [99] , in an area undergoing intraoperative compression by a leg brace [101] , in the perineal region following a fall onto the toilet [146] , in the penile region following circumcision [103] or in a previously healing wound from a pacemaker insertion [170] . It is plausible that nicorandil might also delay healing, establishing a self-perpetuating inflammation; this might explain the existence of a secondary fistulating 
